Pyronaridine-Artesunate versus Chloroquine in Patients with Acute Plasmodium vivax Malaria: A Randomized, Double-Blind, Non-Inferiority Trial
2011

Comparing Pyronaridine-Artesunate and Chloroquine for Malaria Treatment

Sample size: 456 publication 10 minutes Evidence: high

Author Information

Author(s): Poravuth Yi, Socheat Duong, Rueangweerayut Ronnatrai, Uthaisin Chirapong, Pyae Phyo Aung, Valecha Neena, Rao B. H. Krishnamoorthy, Tjitra Emiliana, Purnama Asep, Borghini-Fuhrer Isabelle, Duparc Stephan, Shin Chang-Sik, Fleckenstein Lawrence

Primary Institution: National Malaria Center, Phnom Penh, Cambodia

Hypothesis

Is pyronaridine-artesunate non-inferior to chloroquine in treating uncomplicated P. vivax malaria?

Conclusion

Pyronaridine-artesunate is at least as effective as chloroquine for treating acute uncomplicated P. vivax malaria.

Supporting Evidence

  • The Day-14 cure rate was 99.5% for pyronaridine-artesunate and 100% for chloroquine.
  • Parasite clearance time was shorter with pyronaridine-artesunate (median 23.0 h) compared to chloroquine (32.0 h).
  • Adverse events occurred in 40.4% of patients receiving pyronaridine-artesunate.

Takeaway

This study tested a new malaria treatment and found it works just as well as the old one, but it helps patients get better faster.

Methodology

A phase III randomized, double-blind, non-inferiority trial across five centers in Asia, comparing pyronaridine-artesunate and chloroquine in patients with confirmed P. vivax malaria.

Potential Biases

Potential bias due to exclusion of patients with mixed infections and reliance on microscopy for diagnosis.

Limitations

The study population was restricted and may not reflect the general population of malaria patients.

Participant Demographics

All participants were Asian/Oriental, mostly male (73.7%), with a mean age of 26.7 years.

Statistical Information

P-Value

p<0.0001

Confidence Interval

95%CI 97.5, 100

Statistical Significance

p<0.0001

Digital Object Identifier (DOI)

10.1371/journal.pone.0014501

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication